15811-21-9 Usage
Description
Spiro[2.5]octan-6-one is a unique organic compound characterized by its spiro ring structure and a ketone functional group. It is known for its potential applications in various fields due to its distinct chemical properties.
Uses
Used in Pharmaceutical Industry:
Spiro[2.5]octan-6-one is used as a P2X3 inhibitor for treating P2X3 receptor dysfunction diseases. P2X3 receptors are ion channels found in sensory neurons, and their dysfunction has been associated with various pain-related conditions. By inhibiting these receptors, Spiro[2.5]octan-6-one can help alleviate pain and improve the quality of life for patients suffering from such diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 15811-21-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,8,1 and 1 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 15811-21:
(7*1)+(6*5)+(5*8)+(4*1)+(3*1)+(2*2)+(1*1)=89
89 % 10 = 9
So 15811-21-9 is a valid CAS Registry Number.
15811-21-9Relevant articles and documents
Wuesthoff,Rickborn
, p. 1311 (1968)
PYRROLO[2,3-C]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE
-
, (2018/08/03)
Disclosed are a pyrrolo[2,3-c]pyridine derivative, a preparation method therefor, and use thereof in medicine. Specifically, disclosed are a pyrrolo[2,3-c]pyridine derivative as represented by general formula (1), a preparation method therefor, a pharmaceutical composition comprising the derivative, as well as use thereof as a BRD4 inhibitor in the treatment of related diseases such as cancers, inflammations, chronic liver diseases, diabetes, cardiovascular diseases and AIDS, each substituent in general formula (I) being same as defined in the description.
CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS
-
, (2014/10/03)
Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.